ASCO 2017 Abstracts Released

Myeloma News Roundup: ASCO Abstracts, China Meetings, and iStopMM Clinic Ribbon-Cutting

In his blog this week, IMF Chairman Dr. Brian Durie sifts through the myeloma research abstracts released yesterday in advance of presentations at the upcoming 2017 meeting of the American Society of Clinical Oncology. He also reports on the IMF team’s visit to China and the official opening of the iStopMM® clinic in Iceland, as the IMF’s impact continues to be felt around the world. Read Dr. Durie’s blog.

Register NOW for a FREE "Living Well with Myeloma" Webinar on Nutrition

Register for this FREE 45-minute “Living Well with Myeloma” webinar on Nutrition on Thursday, June 1st at 7 PM ET / 4 PM PT. Hosted by Kylie Buchan of Savor Health, the talk will be followed by a 15-minute Q&A from callers.

 

Updated Prescribing Information for Empliciti

Patients who are scheduled to start Empliciti®/Revlimid®/dexamethasone or are still within their first three cycles with this approved combination will be delighted to know that a shorter infusion time is in their future. Barring infusion reactions, the infusion rate will remain the same for the first day of cycle 1, at approximately 3.5 hours. However, it will decrease to two hours on day 2 of cycle 1, and to one hour on days 3 and 4 of cycle 1 and for all subsequent cycles. Prescribing information now also reflects updated overall survival data. Learn more HERE.

 

Selinexor STORM Study Is Enrolling Patients at Sites Across the US

The STORM clinical trial of selinexor, a novel, first-in-class, orally administered “Selective Inhibitor of Nuclear Export” (SINE™) compound, is for eligible patients who are “penta-refractory” to Velcade®, Kyprolis®, Revlimid®, Pomalyst®, and Darzalex®.  STORM is currently enrolling patients at more than 20 US sites and will be opening in other US and European sites in the coming months.

 

Contact Your Congressional Representative to Take a Stand for Cancer Drug Parity

On May 10th, the International Myeloma Foundation led members of the Patients Equal Access Coalition (PEAC) to Capitol Hill to speak with policymakers about H.R. 1409, the Cancer Drug Parity Act. The groups met with more than 50 different congressional staffers and explained how this bill will help cancer patients obtain their life-saving medications. Contact your Congressional Representative about H.R. 1409 today to show how important this legislation is to you.

 

 

18th Annual J.C. Golf Tournament Tees Off This Weekend - May 20th, 2017

The 18th Annual J.C. Golf Tournament takes place on Saturday, May 20th, 2017 at the Wapicada Golf Club in St. Cloud, Minnesota. The tournament honors Janet “JC” Johnson who passed from myeloma in July 1999. Today, her circle of friends invites you to participate in a day of 18 holes of golf, power cart races, a putting contest, a silent auction, and more. Even if you cannot attend, you can donate here. All funds go toward the International Myeloma Foundation’s research programs.

 


We Would Like to Thank Our Sponsors: Takeda, Celgene, Amgen, and Bristol-Myers Squibb